Virginia will recover $21 million from drug maker Johnson & Johnson and a subsidiary company for alleged misconduct in promoting the use of anti-psychotic drugs and other medicines, the state attorney general’s office announced.
The state is a participant in two separate deals to resolve criminal and civil charges against J&J for efforts to market the drug Risperdol, among other products.
Under the settlements, $10 million is earmarked for restitution to Virginia’s Medicaid program, according to a news release from the office of Attorney General Ken Cuccinelli.
Several states and the federal government charged J&J and the subsidiary with making false and misleading statements about Risperdol’s effectiveness and safety. The companies also were accused of paying illegal kickbacks to doctors and to a major supplier for nursing homes for using the drug.